HCPCS Level II code Q5161 covers the injection of denosumab-kyqq (Aukelso/Bosaya), a 1 mg biosimilar formulation of denosumab used in conditions involving bone resorption. As a coded entry for a biosimilar monoclonal antibody injection, this code matters nationally because biosimilar biologics are increasingly used to manage biologic therapy costs while maintaining clinical outcomes for patients with osteoporosis, cancer-related bone disease, and other indications where denosumab is appropriate.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for denosumab-kyqq, expected sites of service (outpatient infusion/injection centers and physician offices), and the role of a specific HCPCS Level II code in claims processing. The publication outlines benchmarking considerations, common billing scenarios, and policy and coverage implications relevant to payers and provider billing teams.

This summary provides national-level context for coding and billing operations, outlines what to expect in payer coverage reviews, and highlights where to look for policy updates affecting biosimilar injections billed under HCPCS Level II code Q5161. Data not available in the input will be indicated where applicable.